NCT05186129 is a Phase 1 clinical trial of Clopid® 75 mg Tablet in Bioequivalence, sponsored by Center for Bioequivalence Studies and Clinical Research.

Who is sponsoring NCT05186129?

NCT05186129 is sponsored by Center for Bioequivalence Studies and Clinical Research.

What drugs are being tested in NCT05186129?

Interventions in NCT05186129: Clopid® 75 mg Tablet, Plavix® 75mg Tablet.

What condition does NCT05186129 study?

NCT05186129 studies Bioequivalence.

Is NCT05186129 still recruiting?

NCT05186129 is currently completed. Last updated 2 March 2022.

Last reviewed 2022-03-02 · How we verify

NCT05186129

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition

Completed Phase 1 Last updated 2 March 2022

What this trial tests

Phase 1 trial testing Clopid® 75 mg Tablet in Bioequivalence in 36 participants. Completed in 20 April 2018.

Timeline

6 April 2018

Primary endpoint
15 April 2018

20 April 2018

Quick facts

Lead sponsor	Center for Bioequivalence Studies and Clinical Research
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	36
Start date	6 April 2018
Primary completion	15 April 2018
Estimated completion	20 April 2018
Sites	1 location across Pakistan

Drugs / interventions tested

Clopid® 75 mg Tablet — full drug profile →
Plavix® 75mg Tablet

Conditions studied

Bioequivalence — all drugs for Bioequivalence →

Sponsor

Center for Bioequivalence Studies and Clinical Research

Who can join

Adults 18 to 55, male only, with Bioequivalence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the rate and extent of absorption of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® (clopidogrel) 75 mg tablet under fasting condition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bioequivalence

Currently open trials in the same condition.

NCT07096869 — Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Pa · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05186129 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Center for Bioequivalence Studies and Clinical Research
Last refreshed: 2 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05186129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing